LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows 52.4% year over year
Q1 FY2026 capital expenditures of $32K (cash outflow) rose 52.4% year over year. Sequentially, it fell 20.0% from the prior quarter.
Context
- Capital expenditures increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (52K) USD
- Year-over-year change
- +93.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52K) | +93.2% |
| FY2024 | 2024-12-31 | (769K) | -2976.0% |
| FY2023 | 2023-12-31 | (25K) | — |
| FY2022 | 2022-12-31 | 0 | — |
Capital Expenditures vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 capital expenditures of $78K is the 7th largest of the 10 companies compared; the peer median is $411K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $19.91M | +2327.6% | — | 1.7% | |
| LTM Jun 2026 | $3.42M | -81.4% | -18.9% | 94.8% | |
| LTM Mar 2026 | $556K | -70.3% | -68.0% | — | |
| LTM Mar 2026 | $497K | -35.3% | -14.1% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $411K | -74.7% | +29.4% | 2.1% |
| LTM Mar 2026 | $181.36K | +342.3% | +21.8% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $78K | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $16K | — | — | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | — | — | — |
| LTM Jun 2026 | $0 | — | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $411K | -52.8% | -14.1% | 2.1% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 431K | 295K | 3.16M | 0 |
| Change in Working Capital | 86K | (1.31M) | 3.31M | (13.65M) |
| Accounts Receivables | 0 | (154K) | 114K | (268K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | (910K) |
| Other Working Capital | 86K | (1.16M) | 3.2M | (12.47M) |
| Other Non-Cash Items | 11.1M | (4.81M) | 3.49M | 3.33M |
| Operating Cash Flow | (2.73M) | (12.09M) | (53.05M) | (35.21M) |
| Capital Expenditures | 0 | (25K) | (769K) | (52K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (33.99M) | (29.75M) | (44.84M) |
| Sales of Investments | 123K | 6M | 53.75M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 123K | (28.01M) | 23.23M | (39.89M) |
| Debt Repayment | 25.01M | 725K | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 302.56M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.95M) | (2.05M) | (1.69M) | 0 |
| Financing Cash Flow | 22.96M | 33.68M | 38.32M | 302.56M |
| Effect of Forex Changes | 0 | 0 | 0 | (272K) |
| Net Change in Cash | 20.36M | (6.43M) | 8.5M | 227.2M |
| Free Cash Flow | (2.73M) | (12.12M) | (53.82M) | (35.26M) |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.